BUSINESS
Alkem launches pertuzumab biosimilar in India for treatment of breast cancer
In the pivotal phase 3 clinical trial, Alkem’s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator, the company said in a press release.
BUSINESS
Senior care market poised to triple in a decade, turning the space into the next big investment idea
Rising life expectancy, smaller families and growing willingness among seniors to spend on care are creating conditions for a market that could expand several times over in the coming decade.
BUSINESS
Stryker expands India R&D with new innovation centre in Bengaluru
The Whitefield centre will house cross-functional teams and advanced labs focused on robotics, artificial intelligence, digital innovation, and product security, the company said Thursday.
BUSINESS
Dr. Agarwal’s says merger valuation structured through fair and transparent process
The swap ratio—23 AHCL shares (Re 1 face value) for every 2 AEHL shares (Rs 10 face value)—was based on independent valuations by PwC and Bansi Mehta & Co., using globally accepted methods and market price trends, says company
BUSINESS
Bayer goes big on prenatal nutrition, eyes bigger share of India’s consumer health pie
While leveraging enduring appeal of legacy brands such as Saridon and Supradyn, Bayer is also aggressively pushing into India’s Rs 40,000–45,000 crore consumer health market
BUSINESS
Hospitals versus health insurers: Why patients are paying the price
Star Health alone logged 13,300 complaints in FY24, over 10,000 of which were claim-related
BUSINESS
Dr Reddy’s launches novel acid blocker Tegoprazan in India to tap $1 billion market
The rollout follows Dr. Reddy’s exclusive licensing deal with South Korea’s HK inno.N Corp. in 2022 to commercialize Tegoprazan in India and select emerging markets.
BUSINESS
India revokes Novartis' patent for blockbuster heart drug
Vymada is widely prescribed for hypertension and heart failure. For Novartis, the drug is a major revenue driver, generating $7.8 billion in global sales last year
BUSINESS
Brooks Labs looks to exit carbapenem JV, OneSource may buy stake
This move could provide a significant cash infusion for Brooks, which holds a 49% stake in the joint venture with Steriscience Specialties Pvt. Ltd.
BUSINESS
No mandatory relabelling of pre-revised GST stock, NPPA offers ease of compliance to industry
The National Pharmaceutical Pricing Authority (NPPA) clarified that companies can continue selling pre-GST stock without re-stickering, provided they ensure price compliance at the retail level through revised price lists and public communication.
BUSINESS
Apollo Hospitals to acquire IFC stake in AHLL for Rs 1,254 crore; announces Rs 573 crore oncology investment in Gurugram
AHLL consists primary care and diagnostics, birthing & women’s Health (Apollo Cradle), ambulatory care centers, dialysis & dental networks.
BUSINESS
Genomics major lllumina bets on India to power affordable innovation amid global headwinds
"India is not just a cost center—it’s becoming a core innovation engine for us," said Ankur Dhingra, Chief Financial Officer of Illumina told Moneycontrol.
BUSINESS
Dr. Reddy's acquires J&J's Stugeron brand for $50.5 million
The acquisition is a strategic move to strengthen Dr. Reddy's Central Nervous System (CNS) portfolio and expand into the anti-vertigo segment.
BUSINESS
GST rate cut to spur broader access and market growth of Indian pharma market
The sector, which recorded an 8.7% value growth in August 2025, is now bracing for a broader transformation in pricing, access, and patient volumes.
BUSINESS
Eye care chain ASG Hospitals accelerates expansion with IPO plans, eyes 700+ centres across India
The company is also preparing for a potential IPO within 18–24 months, as it consolidates its position in tier-2 and tier-3 cities and deepens its footprint in underserved districts.
BUSINESS
GSK working on affordable vaccines for neglected diseases, partnership with India key: Jamila Louahed
Jamila Louahed - VP, Head Global R&D for Therapeutic Vaccines and Belgium R&D Site Head for GSK outlined how the pharma major's innovations are being deployed to tackle diseases like malaria, typhoid, tuberculosis, and Shigella.
BUSINESS
Somerset Indus Capital Partners nears $250 million close for 3rd healthcare fund
The fund, which focuses on expanding healthcare access to underserved tier 2 and 3 cities, has drawn commitments from a diverse mix of institutional investors
BUSINESS
Delhi chemists want 3-month window to clear pharma stock after GST cut
The Retail Distribution Chemist Alliance has sought immediate relief after GST on medicines was reduced to 5% from 12%, creating an inventory crisis for pharmacies holding stock purchased at the higher rate
BUSINESS
Zydus Life arm reports positive phase-3 trial results in rare liver disease, eyes USFDA nod in 2026
The Ahmedabad-based drugmaker plans to file for USFDA approval in the first quarter of 2026, targeting a market projected to reach $10.8 billion by 2026, growing at a CAGR of 36.3%.
BUSINESS
AHPI asks insurers to resume cashless services, ready to review its advisory
"In view of the discussions today, AHPI urged the insurers that they must immediately restore cashless services at its member hospitals, as the disruption is placing an unfair financial and emotional burden on patients," the association said in a statemen
BUSINESS
Delhi nursing home body alleges 'cartelization' of private insurers, seeks inflation-linked hospital tariffs
The Delhi Medical Association Nursing Home Forum (DMANHF) on Thursday filed a formal complaint with the Insurance Regulatory and Development Authority of India (IRDAI), alleging cartel-like behaviour by private insurers acting through the General Insurance Council (GIC).
BUSINESS
Oncology emerges as top revenue and profitability driver for India’s leading hospital chains
Once a niche segment, cancer care is now central to the strategic plans of Max Healthcare, Apollo Hospitals, and Fortis Healthcare, among others, driven by rising incidence, improved diagnostics, and high-complexity treatments that command premium pricing.
BUSINESS
AiMeD warns blanket GST rejig could hurt domestic MedTech, calls for balanced tax structure
The Association of Indian Medical Device Industry (AiMeD) said that while reducing GST to 5% on high-value equipment like electronics and implants could improve affordability and market reach, applying the same rate to low-margin consumables such as syringes, catheters, and IV sets would worsen the inverted duty structure—where inputs are taxed at 18% and outputs at 5% or 12% leading to margin compression and supply risks.
BUSINESS
GSK re-enters India’s oncology market with Jemperli and Zejula, unveils tiered pricing and patient support program
Bhushan Akshikar, Managing Director of GSK India, said the company is committed to making these therapies accessible through a tiered pricing strategy and a comprehensive patient support program branded Phoenix.
